Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by MASTERINVEST Kapitalanlage GmbH

MASTERINVEST Kapitalanlage GmbH boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 49.6% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,293 shares of the pharmaceutical company’s stock after acquiring an additional 2,749 shares during the quarter. MASTERINVEST Kapitalanlage GmbH’s holdings in Vertex Pharmaceuticals were worth $3,703,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Motiv8 Investments LLC acquired a new position in Vertex Pharmaceuticals during the fourth quarter worth about $26,000. Swiss RE Ltd. acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at approximately $28,000. Eagle Bay Advisors LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at approximately $29,000. IMG Wealth Management Inc. boosted its stake in shares of Vertex Pharmaceuticals by 277.8% during the 4th quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock worth $31,000 after acquiring an additional 50 shares in the last quarter. Finally, Ares Financial Consulting LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $33,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Activity

In other Vertex Pharmaceuticals news, EVP Duncan Mckechnie sold 1,541 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $519.00, for a total value of $799,779.00. Following the completion of the sale, the executive vice president directly owned 11,001 shares of the company’s stock, valued at approximately $5,709,519. The trade was a 12.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Joy Liu sold 1,104 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $425.02, for a total value of $469,222.08. Following the completion of the transaction, the executive vice president owned 20,729 shares of the company’s stock, valued at $8,810,239.58. This trade represents a 5.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 18,874 shares of company stock valued at $8,707,966 in the last 90 days. Insiders own 0.20% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on VRTX. Royal Bank Of Canada raised their price objective on Vertex Pharmaceuticals from $543.00 to $570.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Morgan Stanley boosted their target price on Vertex Pharmaceuticals from $612.00 to $616.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 5th. Maxim Group raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $575.00 target price on the stock in a report on Wednesday, March 18th. Truist Financial raised their price target on Vertex Pharmaceuticals from $542.00 to $560.00 and gave the company a “buy” rating in a research report on Monday. Finally, Wall Street Zen downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, June 28th. Twenty-one research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $559.61.

Vertex Pharmaceuticals Trading Down 0.8%

Vertex Pharmaceuticals stock opened at $476.31 on Wednesday. The stock has a 50-day moving average price of $459.21 and a 200 day moving average price of $458.56. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $533.67. The stock has a market cap of $120.89 billion, a PE ratio of 28.25, a P/E/G ratio of 2.05 and a beta of 0.29.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.24 by $0.23. The company had revenue of $2.99 billion for the quarter, compared to analyst estimates of $2.99 billion. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period in the prior year, the firm earned $4.06 EPS. On average, equities analysts predict that Vertex Pharmaceuticals Incorporated will post 17.03 EPS for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.